PMN Quote, Financials, Valuation and Earnings

Edesa Biotech has a net margin of -- compared to ProMIS Neurosciences's net margin of --. ProMIS Neurosciences's return on equity of -- beat Edesa Biotech's return on equity of --.

ProMIS Neurosciences has a consensus price target of $5.34, signalling upside risk potential of 1087.17%. On the other hand Edesa Biotech has an analysts' consensus of $10.33 which suggests that it could grow by 336.01%. Given that ProMIS Neurosciences has higher upside potential than Edesa Biotech, analysts believe ProMIS Neurosciences is more attractive than Edesa Biotech.

ProMIS Neurosciences has a beta of -0.097, which suggesting that the stock is 109.722% less volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.718%.

ProMIS Neurosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProMIS Neurosciences pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

ProMIS Neurosciences quarterly revenues are --, which are smaller than Edesa Biotech quarterly revenues of --. ProMIS Neurosciences's net income of -$7.3M is lower than Edesa Biotech's net income of -$1.6M. Notably, ProMIS Neurosciences's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProMIS Neurosciences is -- versus 27.25x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

ESSA Pharma has a net margin of -- compared to ProMIS Neurosciences's net margin of --. ProMIS Neurosciences's return on equity of -- beat ESSA Pharma's return on equity of --.

ProMIS Neurosciences has a consensus price target of $5.34, signalling upside risk potential of 1087.17%. On the other hand ESSA Pharma has an analysts' consensus of $1.68 which suggests that it could fall by -10.09%. Given that ProMIS Neurosciences has higher upside potential than ESSA Pharma, analysts believe ProMIS Neurosciences is more attractive than ESSA Pharma.

ProMIS Neurosciences has a beta of -0.097, which suggesting that the stock is 109.722% less volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.559, suggesting its more volatile than the S&P 500 by 55.914%.

ProMIS Neurosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProMIS Neurosciences pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

ProMIS Neurosciences quarterly revenues are --, which are smaller than ESSA Pharma quarterly revenues of --. ProMIS Neurosciences's net income of -$7.3M is lower than ESSA Pharma's net income of -$6.4M. Notably, ProMIS Neurosciences's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProMIS Neurosciences is -- versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of -- compared to ProMIS Neurosciences's net margin of -2177.64%. ProMIS Neurosciences's return on equity of -- beat Lexaria Bioscience's return on equity of -147.06%.

ProMIS Neurosciences has a consensus price target of $5.34, signalling upside risk potential of 1087.17%. On the other hand Lexaria Bioscience has an analysts' consensus of $6.33 which suggests that it could grow by 627.97%. Given that ProMIS Neurosciences has higher upside potential than Lexaria Bioscience, analysts believe ProMIS Neurosciences is more attractive than Lexaria Bioscience.

ProMIS Neurosciences has a beta of -0.097, which suggesting that the stock is 109.722% less volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.756%.

ProMIS Neurosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProMIS Neurosciences pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

ProMIS Neurosciences quarterly revenues are --, which are smaller than Lexaria Bioscience quarterly revenues of $174K. ProMIS Neurosciences's net income of -$7.3M is lower than Lexaria Bioscience's net income of -$3.8M. Notably, ProMIS Neurosciences's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProMIS Neurosciences is -- versus 24.08x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of -- compared to ProMIS Neurosciences's net margin of -867.29%. ProMIS Neurosciences's return on equity of -- beat Xenon Pharmaceuticals's return on equity of -31.52%.

ProMIS Neurosciences has a consensus price target of $5.34, signalling upside risk potential of 1087.17%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $55.23 which suggests that it could grow by 74.68%. Given that ProMIS Neurosciences has higher upside potential than Xenon Pharmaceuticals, analysts believe ProMIS Neurosciences is more attractive than Xenon Pharmaceuticals.

ProMIS Neurosciences has a beta of -0.097, which suggesting that the stock is 109.722% less volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.098, suggesting its more volatile than the S&P 500 by 9.839%.

ProMIS Neurosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProMIS Neurosciences pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

ProMIS Neurosciences quarterly revenues are --, which are smaller than Xenon Pharmaceuticals quarterly revenues of $7.5M. ProMIS Neurosciences's net income of -$7.3M is higher than Xenon Pharmaceuticals's net income of -$65M. Notably, ProMIS Neurosciences's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProMIS Neurosciences is -- versus 175.06x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.